Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects

NCT03722823 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT03722823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03722823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 10, 2018
Completion date
May 7, 2019
Enrollment
37 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment